Maternal serum paraxanthine during pregnancy and offspring body mass index at ages 4 and 7 years

Epidemiology

Volumn 26, Issue 2, 2015, Pages 185-191

  Klebanoff, Mark A ^a   Keim, Sarah A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; PARAXANTHINE; 1,7-DIMETHYLXANTHINE; BIOLOGICAL MARKER; THEOPHYLLINE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; CHILD; CHILDHOOD OBESITY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; FOOD INTAKE; GESTATIONAL AGE; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; PREGNANCY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROGENY; RISK FACTOR; SCHOOL CHILD; SECONDARY ANALYSIS; SMOKING; SPONTANEOUS ABORTION; YOUNG ADULT; BLOOD; FOLLOW UP; MALE; MATERNAL BEHAVIOR; METABOLISM; OBESITY; PRENATAL EXPOSURE; SECOND TRIMESTER PREGNANCY; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CAFFEINE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MATERNAL BEHAVIOR; OBESITY; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; THEOPHYLLINE;

EID: 84924006519     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000220     Document Type: Article

References (33)

1. FDA. Medicines in My Home: Caffeine and your Body. Available at: http://www.fda.gov/downloads/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandingover-the-countermedicines/ucm205286.pdf. Accessed 28 May 2014.
2. Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2005; 105: 110-113.
3. Hinkle S, Laughon S, Catov J, Olsen J, Bech B. First trimester coffee and tea intake and risk of gestational diabetes mellitus: a study within a national birth cohort. BJOG. June 20, 2014. doi: 10.111/1471-0528.12930. [Epub ahead of print].
4. Hoyt AT , Browne M, Richardson S, Romitti P, Druschel C; The National Birth Defects Prevention S. Maternal caffeine consumption and small for gestational age births: results from a population-based case-control study. Matern Child Health J. 2014; 18: 1540-1551.
5. Peck JD, Leviton A, Cowan LD. A review of the epidemiologic evidence concerning the reproductive health effects of caffeine consumption: a 2000-2009 update. Food Chem Toxicol. 2010; 48: 2549-2576.
6. Signorello LB, McLaughlin JK. Maternal caffeine consumption and spontaneous abortion: a review of the epidemiologic evidence. Epidemiology. 2004; 15: 229-239.
7. L eviton A, Cowan L. A review of the literature relating caffeine consumption by women to their risk of reproductive hazards. Food Chem Toxicol. 2002; 40: 1271-1310.
8. L i D-K, Ferber J, Odouli R. Maternal caffeine consumption during pregnancy and the risk of obesity in offspring: a prospective cohort study with 15 years of follow-up. Paper Presented at: Society for Pediatric and Perinatal Epidemiologic Research. Seattle, Washington, 2014.
9. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311: 806-814.
10. Hediger ML, Overpeck MD, Kuczmarski RJ, McGlynn A, Maurer KR, Davis WW. Muscularity and fatness of infants and young children born small- or large-for-gestational-age. Pediatrics. 1998; 102: E60.
11. Buscariollo DL, Fang X, Greenwood V, Xue H, Rivkees SA, Wendler CC. Embryonic caffeine exposure acts via A1 adenosine receptors to alter adult cardiac function and DNA methylation in mice. PLoS One. 2014; 9: e87547.
12. Klebanoff MA, Levine RJ, DerSimonian R, Clemens JD, Wilkins DG. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med. 1999; 341: 1639-1644.
13. N iswander KR, Gordon MJ; National Institute of Neurological Diseases and Stroke. The Women and Their Pregnancies; the Collaborative Perinatal Study of the National Institute of Neurological Diseases and Stroke. DHEW Publication no (NIH) 73-379. Washington: National Institutes of Health; 1972.
14. Klebanoff MA, Levine RJ, Clemens JD, Wilkins DG. Maternal serum caffeine metabolites and small-for-gestational age birth. Am J Epidemiol. 2002; 155: 32-37.
15. Klebanoff MA, Levine RJ, Dersimonian R, Clemens JD, Wilkins DG. Serum caffeine and paraxanthine as markers for reported caffeine intake in pregnancy. Ann Epidemiol. 1998; 8: 107-111.
16. L elo A, Miners JO, Robson R, Birkett DJ. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther. 1986; 39: 54-59.
17. Myrianthopoulos NC; Collaborative Perinatal Project (U.S.). Malformations in Children from One to Seven Years: A Report from the Collaborative Perinatal Project. New York, NY: Liss; 1985.
18. L assmann FM, LaBenz PJ, LaBenz ES. Early Correlates of Speech, Language, and Hearing; the Collaborative Perinatal Project of the National Institute of Neurological and Communicative Disorders and Stroke. Littleton, MA: PSG Pub. Co.; 1980.
19. Branum AM, Parker JD, Keim SA, Schempf AH. Prepregnancy body mass index and gestational weight gain in relation to child body mass index among siblings. Am J Epidemiol. 2011; 174: 1159-1165.
20. R ibas-Fitó N, Gladen BC, Brock JW, Klebanoff MA, Longnecker MP. Prenatal exposure to 1, 1-dichloro-2, 2-bis (p-chlorophenyl)ethylene (p, p'-DDE) in relation to child growth. Int J Epidemiol. 2006; 35: 853-858.
21. (U.S.) Centers for Disease Control and Prevention. A SAS Program for the 2000 CDC Growth Charts (ages 0 to
22. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157: 940-943.
23. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159: 702-706.
24. Diggle P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford statistical science series. Repr. 1994, 1995 (with corrections) ed. Oxford, NY: Oxford University Press; 1995.
25. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010; 29: 1037-1057.
26. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol. 1996; 34: 119-129.
27. Fisher SC, Kim SY, Sharma AJ, Rochat R, Morrow B. Is obesity still increasing among pregnant women? Prepregnancy obesity trends in 20 states, 2003-2009. Prev Med. 2013; 56: 372-378.
28. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Munson ML; Centers for Disease C, Prevention National Center for Health Statistics National Vital Statistics S. Births: final data for 2005. Natl Vital Stat Rep. 2007; 56: 1-103.
29. T ong VT, Dietz PM, Morrow B, et al; Centers for Disease C, Prevention. Trends in smoking before, during, and after pregnancy-Pregnancy Risk Assessment Monitoring System, United States, 40 sites, 2000-2010. MMWR Surveill Summ. 2013; 62: 1-19.
30. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther. 1978; 24: 40-45.
31. G rosso LM, Triche E, Benowitz NL, Bracken MB. Prenatal caffeine assessment: fetal and maternal biomarkers or self-reported intake? Ann Epidemiol. 2008; 18: 172-178.
32. A ldridge A, Bailey J, Neims AH. The disposition of caffeine during and after pregnancy. Semin Perinatol. 1981; 5: 310-314.
33. G rosso LM, Triche EW, Belanger K, Benowitz NL, Holford TR, Bracken MB. Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction. Am J Epidemiol. 2006; 163: 1035-1041.